EC approves Merck’s Keytruda and chemotherapy combination for TNBC patients

Keytruda plus chemotherapy is indicated as first-line treatment for triple-negative breast cancer patients. Credit: Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.